In a today, AHA again urged the Center for Medicare & Medicaid Innovation to delay the start date for its new radiation oncology alternative payment model until Jan. 1, 2022. The complex model, which will be mandatory in certain areas of the country and for which many details are still forthcoming, 鈥渨ould be difficult to implement in three months in the best of circumstances; it will be nearly impossible to implement in three months during a public health emergency,鈥 AHA wrote.

AHA also urged CMMI to reconsider sudden changes to the Bundled Payments for Care Improvement Advanced model effective Jan. 1, especially the move to clinical episode service line groups. 鈥淩equiring model participants to take on risk for large, diverse bundles of episodes 鈥 instead of allowing them to choose individual episodes as is current policy 鈥 will require more financial risk than many participants can currently bear,鈥 AHA . It urged the agency at least to delay the changes for a year so participants can model their impact before having to make participation decisions.  

Related News Articles

Headline
The AHA and Federation of 黑料正能量s Aug. 8 filed an amicus brief in the U.S. District Court for the Eastern District of Texas in support of the U.S.鈥
Headline
The AHA, joined by several other national groups representing 340B hospitals, Aug. 8 urged the Health Resources and Services Administration to extend the鈥
Headline
President Trump Aug. 7 issued an executive order, 鈥淚mproving Oversight of Federal Grantmaking,鈥 requiring government agencies to review new and discretionary鈥
Headline
The AHA today filed an amicus brief in the U.S. Court of Appeals for the D.C. Circuit, defending the Department of Health and Human Services鈥 decision to鈥
Headline
The Senate Appropriations Committee July 31 advanced the fiscal year 2026 appropriations bill for the Departments of Labor, Health and Human Services,鈥
Headline
The Department of Health and Human Services today issued a notice announcing a 340B Rebate Model Pilot Program as a voluntary mechanism for qualifying drug鈥